Vitamin D and Screening Colonoscopy or Polyp Surveillance
NCT ID: NCT02269332
Last Updated: 2024-01-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
298 participants
OBSERVATIONAL
2014-08-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D, Genes and Colorectal Cancer
NCT03370432
DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements
NCT00550563
Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
NCT00399607
Screening Tests in Detecting Colorectal Cancer
NCT00025025
Colorectal Neoplasia Screening w Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Ctrs: The CONCeRN Trial
NCT00339950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Screening Visit:
* Obtain signed Informed Consent Document and HIPAA Authorization (research-driven).
* Record: Date of birth, age, gender, race, ethnicity, current email address, height (in inches), weight (in pounds), waist circumference (in inches) measurement, blood pressure, and whether subject is taking or has taken any vitamin D supplement or derivative, and if so, note the dosage, frequency, and duration of therapy.
* Subjects will be told to fast for at least 10 hours prior to Visit 1
Visit 1 (within two weeks of their screening colonoscopy):
-Subjects will have the following research-driven blood test drawn which include: Serum 25-OH vitamin D via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood will be drawn)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Screening Colonoscopy
Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
Screening Colonoscopy
we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Screening Colonoscopy
we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
Exclusion:
* Previous diagnosis of colorectal cancer, adenomatous polyps, and/or cancer
* Military trainees
* Pregnant women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mike O'Callaghan Military Hospital
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carl Bryce, MD
Role: PRINCIPAL_INVESTIGATOR
Mike O'Callaghan Federal Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mike O'Callaghan Federal Hospital/Nellis Air Force Base
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FWH20140085H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.